Bioverativ Inc (NASDAQ:BIVV) Hits New 12-Month High at $63.65

Bioverativ Inc (NASDAQ:BIVV) shares hit a new 52-week high during mid-day trading on Monday . The company traded as high as $63.65 and last traded at $63.72, with a volume of 699,453 shares trading hands. The stock had previously closed at $63.22.

A number of research analysts recently issued reports on the stock. Zacks Investment Research raised shares of Bioverativ from a “sell” rating to a “hold” rating in a research note on Friday. Evercore ISI began coverage on shares of Bioverativ in a research note on Wednesday. They set an “in-line” rating and a $58.00 target price on the stock. Jefferies Group LLC reaffirmed a “buy” rating and set a $70.00 target price (up previously from $67.00) on shares of Bioverativ in a research note on Wednesday, August 9th. Cowen and Company reaffirmed a “buy” rating and set a $80.00 target price on shares of Bioverativ in a research note on Friday, August 4th. Finally, William Blair began coverage on shares of Bioverativ in a research note on Wednesday, June 28th. They set a “market perform” rating on the stock. One analyst has rated the stock with a sell rating, nine have issued a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $60.43.

The firm has a market cap of $5.96 billion and a P/E ratio of 13.09. The company has a 50-day moving average price of $60.48 and a 200 day moving average price of $55.53.

Bioverativ (NASDAQ:BIVV) last released its earnings results on Wednesday, August 2nd. The biotechnology company reported $0.88 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.71 by $0.17. The business had revenue of $289.10 million for the quarter, compared to the consensus estimate of $269 million. During the same period in the prior year, the business posted $0.59 EPS. Bioverativ’s revenue for the quarter was up 37.5% on a year-over-year basis. Equities research analysts forecast that Bioverativ Inc will post $2.92 EPS for the current year.

In related news, insider Diantha Duvall sold 818 shares of the stock in a transaction on Wednesday, June 28th. The shares were sold at an average price of $60.47, for a total transaction of $49,464.46. Following the transaction, the insider now owns 2,128 shares of the company’s stock, valued at approximately $128,680.16. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Brian S. Posner bought 2,000 shares of Bioverativ stock in a transaction that occurred on Wednesday, May 24th. The shares were acquired at an average cost of $53.86 per share, for a total transaction of $107,720.00. Following the acquisition, the director now owns 4,993 shares in the company, valued at approximately $268,922.98. The disclosure for this purchase can be found here. In the last ninety days, insiders have purchased 97,000 shares of company stock worth $5,435,530.

COPYRIGHT VIOLATION WARNING: “Bioverativ Inc (NASDAQ:BIVV) Hits New 12-Month High at $63.65” was posted by Community Financial News and is owned by of Community Financial News. If you are reading this piece on another publication, it was copied illegally and republished in violation of United States and international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.com-unik.info/2017/08/19/bioverativ-inc-nasdaqbivv-hits-new-1-year-high-at-63-65-updated-updated-updated.html.

About Bioverativ

Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.

What are top analysts saying about Bioverativ Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Bioverativ Inc and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit